2024-10-18 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a global pharmaceutical company that develops, manufactures, and commercializes a wide range of prescription drugs.

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return:** ABBV: 147.55%, VOO: 136.93%
* **Outperformance:** ABBV has outperformed VOO by 10.62% (relative outperformance of 52.63%). 

**2. Recent Price Movement:**

* **Closing Price:** $190.46
* **5-day Moving Average:** $193.19
* **20-day Moving Average:** $194.08
* **60-day Moving Average:** $192.71

**3. Technical Indicators:**

* **RSI:** 46.37 (Neutral)
* **PPO:** -0.26 (Slight bearish signal)
* **Delta_Previous_Relative_Divergence:** -10.8 (Short-term downward trend)
* **Expected Return:** 1.85837839125% (Estimated 5-year return over VOO)

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

* **Recent Earnings:**  ABBV has consistently exceeded analysts' earnings expectations in the last few quarters. The most recent earnings report showed EPS of $2.65 against an expected $2.57.
* **Outlook:**  Analysts remain optimistic about ABBV's future performance, citing strong revenue growth and a robust pipeline of new drugs.

**5. News and Recent Issues:**

* **Recent Market Outlook:** According to FINBOLD, ABBV's market outlook remains positive, supported by its consistent earnings performance and ongoing research and development efforts.
* **Analyst Opinions:**  Analysts largely hold a "buy" or "hold" rating on ABBV, citing its strong financial performance, diversified portfolio, and promising pipeline. 
* **Performance Highlights:** ABBV has consistently delivered strong returns, outperforming the S&P 500 index over the past few years. 

**6. Overall Analysis:**

ABBV is a strong performer in the pharmaceutical industry, demonstrating consistent outperformance compared to the broader market. Despite some recent short-term weakness, its strong fundamentals, positive outlook, and a robust pipeline of new drugs suggest potential for continued growth in the future. However, it is important to note that the pharmaceutical industry is subject to regulatory scrutiny and competition, which could impact the company's performance.

**7. Conclusion:**

ABBV is a well-established pharmaceutical company with a solid track record of strong earnings and revenue growth. The company's consistent outperformance, promising pipeline, and favorable analyst sentiment make it a potentially attractive investment for investors seeking exposure to the pharmaceutical industry. However, it's essential to conduct thorough due diligence and consider individual risk tolerance and investment goals before making any investment decisions.
